Daily Endocrinology Research Analysis
Three impactful endocrinology studies span mechanistic biology, population pharmaco-epidemiology, and endocrine oncology. A mechanistic study identifies a TRAF6–FURIN axis controlling insulin receptor maturation and metabolic control; a nationwide target trial emulation links DPP-4 inhibitors to reduced pulmonary tuberculosis risk in type 2 diabetes; and a JCEM study proposes PBK as a metastasis biomarker and therapeutic target in pheochromocytomas/paragangliomas.
Summary
Three impactful endocrinology studies span mechanistic biology, population pharmaco-epidemiology, and endocrine oncology. A mechanistic study identifies a TRAF6–FURIN axis controlling insulin receptor maturation and metabolic control; a nationwide target trial emulation links DPP-4 inhibitors to reduced pulmonary tuberculosis risk in type 2 diabetes; and a JCEM study proposes PBK as a metastasis biomarker and therapeutic target in pheochromocytomas/paragangliomas.
Research Themes
- Insulin receptor maturation and metabolic signaling
- Antidiabetic therapy and infectious disease risk
- Biomarkers and risk stratification in endocrine tumors
Selected Articles
1. Golgi-associated TRAF6 as a regulator of protein convertase FURIN for insulin receptor precursor processing.
This mechanistic study identifies TRAF6 as a Golgi-associated E3 ligase that ubiquitinates FURIN, reducing FURIN levels and limiting pro-INSR processing. Genetic inactivation of TRAF6 preserves mature insulin receptor, enhances insulin signaling, improves muscle glucose uptake, suppresses hepatic gluconeogenesis, and also modulates PCSK9 processing, linking the pathway to cholesterol metabolism.
Impact: Revealing a druggable TRAF6–FURIN axis that controls insulin receptor maturation provides a novel mechanism underlying insulin resistance and integrates glucose and lipid pathways.
Clinical Implications: Targeting TRAF6 or stabilizing FURIN could restore insulin receptor levels and improve insulin sensitivity; the PCSK9 link suggests broader metabolic benefits. Translation requires human validation and safe modulators.
Key Findings
- TRAF6 inactivation prevents palmitic acid/high-fat diet–induced reduction of insulin receptor and enhances insulin signaling.
- TRAF6 ubiquitinates the cytosolic tail of FURIN at the Golgi, promoting lysosomal degradation and reducing pro-INSR processing.
- Improved insulin signaling increases muscle glucose uptake and suppresses hepatic gluconeogenesis in vivo.
- The TRAF6–FURIN axis also regulates PCSK9 processing, linking to cholesterol metabolism.
Methodological Strengths
- Genetic inactivation models demonstrating causality across tissues (muscle and liver).
- Cellular mechanistic mapping of TRAF6–FURIN interaction at the Golgi with functional metabolic readouts.
Limitations
- Preclinical study without human validation; translational relevance requires clinical corroboration.
- Specific ubiquitination sites and potential off-target effects of modulating TRAF6 were not delineated.
Future Directions: Define ubiquitination sites, develop selective TRAF6 modulators, and test metabolic efficacy and safety in human cells and early-phase trials; evaluate lipid benefits via PCSK9 modulation.
Obesity is a major pathological factor that induces insulin resistance and consequent type 2 diabetes through multiple mechanisms. Inactivation of the insulin receptor (INSR) contributes to the development of insulin resistance, whose protein level is down-regulated in obesity through as yet-undefined mechanisms. Here we show that the E3-ligase TRAF6 is a critical regulator of INSR maturation, whose inactivation prevents palmitic acid- or high-fat diet-induced diminution of the INSR. Consequently, genetic inactivation of TRAF6 enhances insulin signaling that further increases muscle glucose uptake and inhibits hepatic gluconeogenesis. TRAF6 inactivation increases the proprotein convertase FURIN that controls the processing of pro-INSR to mature INSR.
2. Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data.
In a nationwide target trial emulation including 328,842 matched pairs with T2DM, DPP-4 inhibitor use was associated with a lower risk of incident pulmonary TB (adjusted HR 0.85, 95% CI 0.81–0.90), with longer cumulative exposure linked to greater risk reduction. Kaplan–Meier curves confirmed a lower cumulative TB incidence among users.
Impact: Links a widely used antidiabetic class to reduced TB risk using rigorous emulation of a target trial at national scale, informing therapeutic choices in infection-prone populations.
Clinical Implications: In TB-endemic settings or in patients at elevated TB risk, DPP-4 inhibitors may be preferred when clinically appropriate. Findings support integrating infection risk into antidiabetic drug selection and warrant confirmatory pragmatic trials.
Key Findings
- Among 328,842 matched pairs, DPP-4 inhibitor users had lower pulmonary TB incidence (aHR 0.85, 95% CI 0.81–0.90).
- Incidence rates were 1.93 vs 2.18 per 1,000 person-years (users vs non-users) with mean follow-up 5.06 vs 4.05 years.
- Longer cumulative duration of DPP-4 inhibitor use correlated with further TB risk reduction.
- Kaplan–Meier analysis showed significantly lower cumulative TB incidence in users (log-rank p < 0.001).
Methodological Strengths
- Target trial emulation with large, nationwide administrative database and time-to-event modeling.
- Extremely large sample size with duration–response analysis and robust matching.
Limitations
- Observational design susceptible to residual confounding and indication bias despite emulation.
- Outcome and exposure ascertainment rely on claims data; generalizability beyond Taiwan requires caution.
Future Directions: Conduct pragmatic randomized or quasi-experimental studies, assess class-specific effects across diverse populations, and explore immunologic mechanisms of DPP-4 inhibition on TB susceptibility.
BACKGROUND: Diabetes mellitus increases the risk of developing tuberculosis (TB) and negatively affects TB treatment outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in glycemic control but can also modulate immune pathways involved in immune-mediated diseases. Considering the immunoregulatory effects of DPP-4 inhibitors, this emulated target trial compared the risk of pulmonary TB in users and non-users of DPP-4 inhibitors with type 2 diabetes mellitus (T2DM). METHODS: We identified 328,842 pairs of DPP-4 inhibitor users and non-users from Taiwan's National Health Insurance Research Database from January 1, 2007, and December 31, 2019. Cox proportional hazard models were used to determine the risk of new-onset pulmonary TB between the study and control groups. RESULTS: The follow-up duration was 5.06 years for DPP-4 inhibitor users and 4.05 years for non-users. The incidence rates of new-onset pulmonary TB were 1.93 and 2.18 cases per 1,000 person-years in DPP-4 inhibitor users and non-users, respectively.
3. PBK as a potential biomarker and therapeutic target for metastatic pheochromocytomas and paragangliomas.
PBK expression correlates with metastatic behavior, proliferative index, SDHB mutation, and worse metastasis-free survival in PPGLs. A PBK index ≥3% independently predicts metastasis and markedly improves risk model AUC to 0.951; PBK knockdown reduces viability, induces S-phase arrest, and suppresses migration/invasion via EMT and oncogenic pathway modulation.
Impact: Introduces a clinically measurable biomarker (PBK index) with strong predictive performance for metastasis in PPGLs and mechanistic data supporting PBK as a drug target.
Clinical Implications: Incorporating PBK index into PPGL risk models could refine surveillance and guide adjuvant strategies; PBK inhibitors or pathway modulation may offer therapeutic avenues for metastatic disease.
Key Findings
- Higher PBK expression associates with metastasis, higher Ki-67, SDHB mutations, and shorter metastasis-free survival.
- PBK index remained an independent predictor of metastasis (OR 1.40, P=0.016) after adjustment.
- PBK index ≥3% substantially improved metastasis prediction when combined with established predictors (AUC 0.951).
- PBK knockdown reduced viability, induced S-phase arrest with p53/p21 upregulation, and suppressed migration/invasion via EMT and MAPK/Rap1/TGF-β pathways.
Methodological Strengths
- Integration of public transcriptomic datasets with validation in clinical PPGL cohorts and multivariable modeling.
- Mechanistic in vitro assays corroborating biological plausibility of PBK as a driver of metastasis-related traits.
Limitations
- Retrospective analyses; external prospective validation of the PBK cutoff and assay standardization are needed.
- Functional work is limited to cell models without in vivo validation.
Future Directions: Prospective, multi-center validation of PBK index, development of PBK inhibitors, and in vivo studies to assess anti-metastatic efficacy and safety.
BACKGROUND: Metastasis is the major determinant of prognosis in pheochromocytomas and paragangliomas (PPGLs), yet reliable biomarkers remain lacking. PDZ-binding kinase (PBK), a serine-threonine kinase of the MAPKK family, regulates mitosis and oncogenic signaling, and has been implicated in tumorigenesis and progression in multiple malignancies. However, its role in PPGLs has not been explored. METHODS: Bioinformatic analyses of public transcriptomes identified a novel metastasis-related molecule, PBK, and investigated its correlation with clinical features and prognosis, with findings further validated in clinical PPGL cohorts. PBK index, defined as the percentage of positive PBK staining, was evaluated for independent significance and performance for metastasis prediction in multivariate Cox models. In vitro assays were conducted on PC-12 cells to explore the function of PBK and potential mechanisms. RESULTS: Elevated PBK expression showed correlations with metastasis, higher Ki-67 labeling index, SDHB mutations, and shorter metastasis-free survival in both public datasets and clinical cohorts. After adjusting for established risk factors, PBK index remained an independent predictor for metastasis (OR: 1.40, P=0.016). PBK index≥3% substantially improved predictive performance when combined with established predictors (AUC=0.951). In vitro, PBK silencing significantly impaired PC-12 cell viability, accompanied by S phase arrest and upregulation of p53 and p21. PBK silencing also suppressed cell migration and invasion by downregulating MMP2/9, disrupting EMT and other oncogenic pathways, including the MAPK, Rap1, and TGF-β signaling. CONCLUSIONS: PBK serves as a novel metastasis-related biomarker and a promising therapeutic target in PPGLs. Incorporation of PBK index into risk models may refine metastasis prediction.